English EN Spanish ES French FR Chinese (Simplified) ZH-CN
Print Friendly, PDF & Email

NCT/Study#

NCT04310592 /

CYNK-001-AML-001

A Phase I Multi-Dose Study Of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) In Adults With Actively Diagnosed Primary Or Secondary Acute Myeloid Leukemia (AML) In Morphologic Complete Remission With Minimal Residual Disease (MRD)

DISEASE GROUP:
Leukemia
current phase:
Phase I
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: